Evommune, Inc.(EVMN)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$7.63
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for EVMN

11/13/2026: EVMN (1-star) is currently NOT-A-BUY. Pass it for now.

Evommune, Inc. is a clinical-stage biotechnology stock focused on developing novel oral small molecules and biologics for chronic inflammatory diseases. The company's primary strengths include a differentiated pipeline targeting upstream immune drivers, such as EVO301 and EVO756, alongside a healthy cash runway secured through recent public financing. Its core growth story centers on advancing multiple mid-stage clinical trials toward upcoming value-inflection data catalysts. However, the company faces substantial execution, clinical trial attrition, and competition risks typical of pre-commercial biotech enterprises. Evommune suits risk-tolerant growth investors willing to monitor upcoming clinical milestones and regulatory developments closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitEvommune offers high-growth potential driven by clinical trial catalysts across a burgeoning immunology pipeline.
Momentum investorStrong fit while signal remains positiveShort-term price action reacts sharply to clinical data announcements and biotech sector sentiment trends.
Value investorWeak fitThe company lacks current commercial earnings, positive cash flow, or traditional valuation metrics.
Dividend investorWeak fitEvommune reinvests all capital into research and development and pays no dividends.
Low-risk investorWeak fitClinical-stage biotechnology stocks carry high binary risks associated with drug development failures and market volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech shares experience severe price swings around clinical trial readouts and regulatory updates.
Valuation riskHighValuations are speculative and decoupled from traditional price-to-earnings fundamentals.
Competition risk (biotech clinical development)Medium / highThe company faces intense rivalry from larger drug developers working on parallel immunology pathways.
Business qualityMediumWhile backed by strong science, the enterprise lacks a commercial product footprint.
Dividend incomeLow / noneNo dividend yield is available or anticipated for income-focused investors.
Execution riskHighSuccess depends completely on complex clinical trial execution and regulatory clearance.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 315.50M USD
Price to earnings Ratio -
1Y Target Price 21.89
Price to earnings Ratio -
1Y Target Price 21.89
Volume (30-day avg) 947.0K shares
Beta -
52 Weeks Range 4.94 - 33.20
Updated Date 11/15/2026
52 Weeks Range 4.94 - 33.20
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.83

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -26.45%
Avg. Invested days 14
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
EVMN receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft quantitative characteristics, and weak price momentum.

Company Fundamentals

★★★★★
EVMN has moderate overall fundamentals (3 stars), with soft financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong revenue growth (+85.7%) is partially offset by slightly negative earnings growth (-3.1%), weak cash generation (FCF margin -589.8%), weak profitability (net margin -529.8%).

Financial Health Rating

★★★★★
EVMN's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 60.3%). Cash strength is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is EVMN's strongest growth driver at +85.7% FY2025 versus FY2024 (strong, 5 stars). By comparison, while earnings growth (-3.1%, slightly negative) and free-cash-flow growth (-31.6%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 93.6% and approximately 54.8% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 2.82% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

EQT Fund Management S.à r.l. 14.54%
RA Capital Management, LLC 9.61%
T. Rowe Price Associates, Inc. 5.33%
Pivotal bioVenture Partners Investment Advisor LLC 5.30%
JPMorgan Chase & Co 4.27%

Unit Economics (Per $1K Revenue)

★★★★★
EVMN generates approximately $1,000 of gross profit, $-6,236 of operating income, and $-5,898 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.00%

Quantitative Style Profile

★★★★★
EVMN has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Clinical Research and Development CollaborationsEarly-stage development partnerships, licensing agreements, and occasional research grants.Evommune does not sell commercial drugs yet; revenue is minimal and operations are funded by investor capital and public offerings.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 154.58M
Price to Sales(TTM) -
Enterprise Value 154.58M
Price to Sales(TTM) -
Enterprise Value to Revenue 9.84
Enterprise Value to EBITDA -
Shares Outstanding 41.35M
Shares Floating 22.65M
Shares Outstanding 41.35M
Shares Floating 22.65M
Percent Insiders 2.82
Percent Institutions 93.59

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.